Spark Therapeutics Inc. (Nasdaq: ONCE) reported upbeat data from a Phase 3 trial of SPK-RPE65 sending the stock price soaring $9.23 to $53.16.
Spark Therapeutics reports upbeat data
October 05, 2015 at 14:17 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.